SBI Securities Co. Ltd. Purchases Shares of 1,018 Glaukos Co. (NYSE:GKOS)

SBI Securities Co. Ltd. purchased a new stake in Glaukos Co. (NYSE:GKOS) in the 4th quarter, HoldingsChannel.com reports. The fund purchased 1,018 shares of the medical instruments supplier’s stock, valued at approximately $153,000.

Several other large investors have also recently bought and sold shares of GKOS. IFP Advisors Inc bought a new position in Glaukos in the 4th quarter valued at $43,000. Asset Planning Inc bought a new position in Glaukos in the 4th quarter valued at $90,000. Harvest Fund Management Co. Ltd raised its position in shares of Glaukos by 2,263.2% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after buying an additional 860 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of Glaukos by 275.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier’s stock valued at $164,000 after buying an additional 807 shares in the last quarter. Finally, KBC Group NV raised its position in shares of Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after buying an additional 201 shares in the last quarter. 99.04% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on GKOS shares. Morgan Stanley cut shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective on the stock. in a research report on Monday, December 2nd. BTIG Research raised their price objective on shares of Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Stifel Nicolaus raised their price objective on shares of Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research report on Tuesday, December 31st. Truist Financial raised their price objective on shares of Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Finally, UBS Group started coverage on shares of Glaukos in a research report on Friday, December 6th. They set a “buy” rating and a $182.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $163.25.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $104.14 on Friday. The company’s fifty day moving average is $146.88 and its 200 day moving average is $138.89. Glaukos Co. has a 52 week low of $84.08 and a 52 week high of $163.71. The stock has a market cap of $5.89 billion, a PE ratio of -36.29 and a beta of 1.04. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The firm had revenue of $105.50 million during the quarter, compared to analysts’ expectations of $100.72 million. Research analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current year.

Insider Buying and Selling at Glaukos

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Joseph E. Gilliam sold 3,328 shares of Glaukos stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $149.85, for a total transaction of $498,700.80. Following the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at $15,310,024.65. The trade was a 3.15 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,744 shares of company stock worth $2,792,151. 6.40% of the stock is currently owned by company insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.